IV Vidaza Approved; Oral Formulation to Be Tested
IV Vidaza Approved; Oral Formulation to Be Tested
BOULDER, ColoradoThe FDA has approved Pharmion Corporation's NDA supplement to add IV use as a new route of administration for the company's DNA demethylation agent Vidaza (azacitidine) for the treatment of myelodysplastic syndrome (MDS). Hypomethylation may restore normal function to genes critical for differentiation and proliferation. A parenteral formulation of the agent is currently available.
The company also received an IND for the first human trial of oral Vidaza. The phase I trial will include patients with MDS, acute myelogenous leukemia, and malignant solid tumors.
Articles in this issue
Peptide-Based Breast Ca Vaccines Promising in Early Trials
Diagnostic Dilemma: GI Disease
Imatinib Responses in CML May Take Time
IV Vidaza Approved; Oral Formulation to Be Tested
Study Confirms Avastin Advantage in Advanced NSCLC
Legal Services Should Be a Component of Standard Cancer Care
Mouse Virus Evidence Suggests Viral Basis for Breast Ca
Groups Oppose Ruling on Access to Experimental Drugs
Satellite Allows Digital Mammography Screening for Rural Native Americans
Nexavar Effective in Advanced HCC: Phase III Trial Stopped
H&N Ca Patients With CR to CRT May Not Need Surgery
Two Sets of Researchers Find Herceptin Cost Effective
Family-Based Testing Strategy May Better Detect HNPCC
More 'Promacs,' Worse Outcome
Brachytherapy Balloon Can Be Placed After Final Pathology
Recent Videos
Related Content
